iQ&A Interactive Medical Intelligence Zone for Familial Hypercholesterolemia
The Interactive Medical Intelligence Zone is a needs assessment-driven continuing medical education (CME) activity that utilizes national and international experts to provide evidence-based, guideline-consistent, and practice behavior-changing information focused on critical and challenging topics in clinical medicine.
To ensure that the educational content of iQ&A programs will address practice gaps in clinical medicine, improve patient outcomes, and positively guide clinical practice strategies, international experts, usually in a roundtable format, will respond to questions submitted and/or generated by practitioners at CME mega-symposia, national congress, association meetings, or as part of on-line, enduring CME programs.
Questions reflecting the clinical needs of practitioners are then answered, analyzed, and discussed by international experts, who provide evidence-based and clinically relevant guidance that is independently of commercial sources or the program sponsor.
The iQ&A platform stresses:

  • Needs assessment-driven CME content
  • Evidence-based analysis
  • Expert-based guidance and consultation
  • Compliance adherence
  • Independence of content generation
  • Landmark trials
  • Association-generated practice management guidelines
  • Quality of care improvement
  • Practice gap improvement

Program Medium
Internet-based program


Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period April 22, 2013 through April 22, 2015, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 128 segments, totaling 4 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Estimated Time to Complete Educational Activity

4.0 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the management of familial hypercholesterolemia.

Release Date

April 22, 2013

Expiration Date

April 22, 2015

Intended Audience

This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with familial hypercholesterolemia.

This constituency of HCPs shall include the following audience:

  • Cardiologists
  • Atherosclerosis experts
  • Lipidologists
  • Thrombosis medicine specialists
  • Preventive medicine specialists
  • Pediatric cardiovascular specialists
  • Endocrine and cardiometabolic disease specialists
  • Cardiology department program directors
  • Clinical geneticists
  • Clinical cardiovascular pharmacists
  • Related specialists



Registration

Participation in this iQ&A interactive Medical Intelligence Zone for Familial Hypercholeterolemia is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an educational grant from Genzyme.



Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources, LLC. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

Professor Gerd Assmann, MD
Professor of Clinical Chemistry and Laboratory Medicine
University of Münster
Executive Director, Institute for Arteriosclerosis Research
Münster, Germany

Nothing to disclose

 

Philip Barter, MD, PhD
Director, The Heart Research Institute
Professor of Medicine
University of Sydney
Sydney, Australia

Consultant: AstraZeneca Pharmaceuticals LP; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche
Speaker/Speaker’s Bureau: AstraZeneca Pharmaceuticals LP; Kowa Company Ltd.; Merck & Co., Inc.; Pfizer Inc; Roche
Research Support: Merck & Co., Inc.

 

Dirk Blom, PhD
Division of Lipidology
Department of Medicine
University of Cape Town
Cape Town, South Africa
  
Nothing to disclose

 

Philippe Costet, PhD
Head, Molecular Investigations of Dyslipidemia Laboratory
INSERM
Head, Metabolic Functions
CARDIEX
Nantes, France

Nothing to disclose

 

Guy De Backer, MD, PhD, FACC
Professor Emiritus
Division of Cardiology
University of Ghent
Ghent, Belgium

 

Peter J. Havel, PhD
Professor, Department of Molecular Biosciences
and Department of Nutrition
University of California, Davis
Davis, CA

Nothing to disclose

 

Robert A. Hegele, MD, FRCPC, FACP, FAHA, FCAHS 
Director & Scientist, Martha G. Blackburn 
Cardiovascular Genetics Laboratory, Robarts Research Institute
Jacob J. Wolfe Distinguished Medical Research Chair
Edith Schulich Vinet Canada Research Chair (Tier 1) in Human Genetics
Distinguished Professor of Medicine and Biochemistry
University of Western Ontario
London, Ontario, Canada

Consultant: Abbott Laboratories; Merck & Co., Inc.; Roche
Speaker/Speaker’s Bureau: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Merck & Co., Inc.; Pfizer Inc; Schering-Plough Corporation; Sunovion Pharmaceuticals Canada Inc.
Research Support: Canadian Institutes of Health Research and the Heart and Stroke Foundation of Ontario

 

Professor Ulf Landmesser, MD
Senior Consultant Cardiologist
Head of Acute and Co-Head of Interventional Cardiology
Head of Cardiovascular Research
Department of Cardiology
University Hospital
Zurich, Switzerland
Deputy Editor, European Heart Journal

Nothing to disclose

 

Professor Željko Reiner, MD, PhD, FRCP(Lond), FESC, FACC
Chairman, Science and Guidelines Committee
European Association For Cardiovascular Prevention and Rehabilitation
President, Croatian Atherosclerosis Society
Director, University Hospital Center Zagreb
Zagreb, Croatia

Consulting or research support: Bayer Healthcare, AstraZeneca, Pfizer, Merck Sharpe & Dohme, and Abbott.

 

Cesare Sirtori, MD, PhD
Dean of the School of Pharmacy
Department of Pharmacological Sciences
University of Milan
Mila, Italy

Nothing to disclose

 

Dr Anton F. Stalenhoef , MD
Professor of Medicine
Department of Internal Medicine
Head of the Section Vascular Medicine of the Department of
Internal Medicine
Radboud University Nijmegen Medical Centre
Nijmegen, The Netherlands

Consultant: Genzyme Corporation
Speaker’s Bureau: Roche

 

Christian Weber, MD
Director, Institute for Cardiovascular Prevention
Chair in Vascular Medicine
Ludwig-Maximilians-University
Munich, Germany
Professor
Cardiovascular Research Institute Maastricht
Maastricht University

Nothing to disclose

 

Robert H. Eckel, MD
Director of the Lipid Clinic
University of Colorado Hospital
Professor of Medicine
University of Colorado Anschutz Medical Campus
Director Lipid Clinic, University Hospital
Denver, CO

Grant/Research Support: GSK; Consultant: Amarin, Amylin, Eli Lilly, Esperion, Essentialis, Genentech, Genfit, Haptocure, J&J, Novo Nordisk, Regulus, sanofi-aventis, Vivus

 

Maria Cristina de Oliveira Izar , MD
Department of Medicine
Section of Lipids, Atherosclerosis and Vascular Biology
Cardiology Division
Federal University of Sao Paulo
Sao Paulo, Brazil

Nothing to disclose

 

Raul D. Santos, MD, PhD
Director Lipid Clinic Heart Institute (InCor)
University of Sao Paulo Medical School Hospital
Sao Paulo, Brazil

Speaker/Consultant Honoraria: Pfizer, Astra Zeneca, Merck, Glaxo Smith Kline Abbott , ISIS, Genzyme, Biolab, Bristol Myers Squibb and Novartis

 

Stephen Daniels, MD, PhD
Pediatrician in Chief
L. Joseph Butterfield Chair of Pediatrics
Chairman of Pediatrics
Children’s Hospital of Colorado
Professor
University of Colorado
Denver, CO

Nothing to disclose

 


Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.


Educational Objectives

Upon completion of this activity, participants will be able to:

  • Apply the Simon Broome Register criteria to confirm the diagnosis of heterozygous familial hypercholesterolemia (HeFH);
  • Determine the LDL-C target goals for patients with HeFH, based on a number of criteria and consensus recommendations including risk categories and/or maximally attainable LDLC reductions;
  • Understand the clinical implications of the underlying genetic mutations, including LDLR and APOB mutations, that underpin impaired LDL receptor function or LDL removal in patients with HeFH;
  • Employ currently available, statin-based treatment regimens to achieve LDL-C target goals for HeFH, and be able to act upon the indications and clinical triggers for more aggressive LDLC lowering in high risk patients
  • Understand the molecular mechanisms of action (MOA) and potential clinical implications of novel, antisense oligonucleotides (ASOs) as therapeutic agents that may be used instead of, or in combination with, traditional lipid-lowering agents in CVD and hypercholesterolemic patients; and, especially in patients carrying inherited disorders of lipoprotein metabolism, including FH, FDB, ARH, mutations in the PCSK9 gene, sitosterolemia, cholesterol 7α-hydroxylase deficiency and polygenic hypercholesterolemia;
  • Deploy ASOs in patients with inherited lipoproteins disorders, based on a scientific understanding of their efficacy on LDL-C reduction as compared to traditional statins, their pharmacokinetic and pharmacodynamics profiles, metabolism, side effects, drug-drug interactions, usefulness in statin-intolerant patients, and clinical triggers for their deployment as adjunctive therapy in hypercholesterolemia;
  • Apply the results, conclusions, and findings of landmark clinical trials evaluating the safety and efficacy of ASOs for optimizing target goal attainment in patients with FH;
  • Understand the clinical rationale and metabolic implications of targeting specific lipid moieties, such as apolipoprotein B-100 (apoB-100), the major protein moiety of the atherogenic lipoproteins LDL and Lp(a), as the ideal target for antisense therapy;
  • Detail a scientifically rigorous, mechanistically and clinically relevant understanding of ASOs, and the metabolic effects that result when short, single-stranded synthetic analogs of nucleic acids that bind to a target mRNA, preventing its translation and thereby inhibiting protein synthesis, and the potential application of such MOAs to treatment of patients with FH;


Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2013 by CMEducation Resources, LLC All rights reserved. 

Reproduction, distribution, or translation without express written permission is strictly prohibited. 

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity. 

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations. 

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman. 

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC